Sayeh Nikpay, PhD, MPH, explains the origins of 340B, how safety net clinics as well as large hospitals became participants in the program, and the possibility of getting rid of the program altogether.
Neeraj Agarwal, MD discusses management decisions for patients with advanced or metastatic prostate cancer, including weariness in using ADT for many patients with comorbidities and how clinicians are currently weighing existing regimens.
Daniel Goldstein, MD, discusses the ability of interventional pharmacoeconomics to lower drug costs and increase access around the world, as well as the dilemma physicians face for treating patients with a person-centered vs a population health approach.
I have been a fan of John Mandrola, MD for years, and I am not exaggerating. He is a cardiac electrophysiologist at Baptist Health (Louisville, KY) who truly understand clinical medicine but I have yet to meet someone as patient-centric as John. He visits with me on the podcast and explains how all medical evidence
No one, and I mean no one, understands drug pricing and the policies around regulating them like Stacie Dusetzina, PhD, from the Department of Health Policy at Vanderbilt University School of Medicine, does. So, I was fortunate to have her as my guest on the podcast to discuss the “desensitization” of society to cancer prescription
Michael Thompson, MD, PhD, Advocate Aurora Health Care, discusses social determinants of health, eligibility criteria, and other barriers to clinical trial enrollment in the community setting, as well as the importance of real-world evidence in moving the needle for oncology care. Michael has had an amazing career so far and has been serving on the
Gilberto Lopes, MD, editor-in-chief of the Journal of Global Oncology, Professor of Medicine, world renowned expert in lung cancer, and creator of a global oncology program at the University of Miami Sylvester Comprehensive Cancer Center, discusses the intersection of globalization and localization of cancer care and measuring success in a global oncology program, among other
Sumanta (Monty) Kumar Pal, MD, the youngest professor I have ever known and a GU medical oncologist at City of Hope, breaks down diagnosing and administering definitive therapy for localized muscle-invasive bladder cancer, postoperative management options for patients with residual disease, optimizing treatment decisions for metastatic disease, and more. Monty is an amazing researcher, mentor,
the award-winning hematologist and a medical oncologist who hosted Outspoken Oncology, a podcast featuring candid discussions of the most pressing, and often controversial, medical topics. Combining his background in cancer research and health care advocacy, Dr. Nabhan brings a unique and powerful perspective to current medical events.
